Epidermolysis Bullosa - Epidemiology Forecast - 2034

Epidermolysis Bullosa - Epidemiology Forecast - 2034

Key Highlights

Epidermolysis Bullosa is slightly more prevalent in males than females, with approximately 14,000 cases reported in the US in 2023.

In 2023, the majority of type-specific cases were attributed to Epidermolysis Bullosa Simplex. Dystrophic Epidermolysis Bullosa accounted for 30% of prevalent cases, while Junctional Epidermolysis Bullosa constituted just 5% of the observed cases.

In 2023, Japan accounted for approximately 4% of the Epidermolysis Bullosa cases among the 7MM.

Among Epidermolysis Bullosa cases in the US in 2023, individuals aged 0-9 years represented approximately 45% of the reported cases.

DelveInsight’s “Epidermolysis Bullosa – Epidemiology Forecast – 2034” report delivers an in-depth understanding of Epidermolysis Bullosa, historical and forecasted epidemiology trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Geography Covered

The United States

EU4 (Germany, France, Italy, and Spain) and the United Kingdom

Japan

Study Period: 2020–2034

Epidermolysis Bullosa Disease Understanding and Treatment Algorithm

Epidermolysis Bullosa Overview

Epidermolysis Bullosa is a genetic skin disorder characterized by extreme skin fragility and blistering in response to minimal friction or trauma. The condition is caused by genetic mutations that affect the proteins responsible for maintaining the structural integrity of the skin. The severity of Epidermolysis Bullosa can vary widely, ranging from mild to life-threatening, depending on the specific subtype.

Epidermolysis Bullosa Diagnosis

The patient journey of Epidermolysis Bullosa begins with the onset of symptoms, such as frequent skin blistering and slow wound healing. Concerned caregivers seek medical attention, leading to a clinical examination by a healthcare professional to assess skin fragility and blister distribution. Skin biopsy and genetic testing are performed to confirm the diagnosis and classify the specific Epidermolysis Bullosa subtype. Upon diagnosis, a multidisciplinary management plan is developed involving dermatologists, wound care specialists, nutritionists, and physiotherapists. Emotional support and counseling are provided to cope with the challenges of living with Epidermolysis Bullosa. Long-term care and regular follow-ups are necessary to monitor skin health and prevent complications. Access to medical resources and expertise can influence the journey’s duration and outcomes. Early diagnosis is crucial for timely intervention and improving the patient’s quality of life.

Further details related to diagnosis are provided in the report…

Epidermolysis Bullosa Epidemiology

The Epidermolysis Bullosa epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by total prevalent cases of Epidermolysis Bullosa, total diagnosed prevalent cases of Epidermolysis Bullosa, gender-specific cases of Epidermolysis Bullosa, age-specific cases of Epidermolysis Bullosa, and type-specific cases of Epidermolysis Bullosa in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan from 2020 to 2034.

The total prevalent cases of Epidermolysis Bullosa in the 7MM comprised approximately 46,800 cases in 2023 and are projected to increase during the forecast period (2024–2034).

The United States contributed to the largest prevalent cases of Epidermolysis Bullosa i.e., 31,000 cases in 2023.

Among EU4 countries in 2023, Germany had the highest prevalence of Epidermolysis Bullosa, followed by Italy.

In Japan, the age group of >19 years accounted for the least number of cases i.e., around 400 cases in 2023.

KOL Views

To keep up with current epidemiology trends, we take KOLs and SMEs’ opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry experts contacted for insights on Epidermolysis Bullosa epidemiology insights, include Medical/scientific writers; Dystrophic Epidermolysis Bullosa Research Association of America; Dermatologist and Professors; National Epidermolysis Bullosa Registry, and Center for Blistering Diseases, St John’s Institute of Dermatology, NHS Foundation Trust, Departments of Dermatology, and others.

Delveinsight’s analysts connected with 30+ KOLs to gather insights; however, interviews were conducted with 10+ KOLs in the 7MM. Centers such as the Center for Blistering Diseases, Department of Allergology and Dermatology, Department of Dermatology, Medical Center, etc., were contacted. Their opinion helps understand and validate Epidermolysis Bullosa epidemiology trends.

Scope of the Report

The report covers a segment of key events, an executive summary, descriptive overview of Epidermolysis Bullosa, explaining its causes, signs and symptoms, pathogenesis, and diagnostic approaches.

Comprehensive insight into the epidemiology segments and forecasts, disease progression has been provided.

The report provides an edge while developing business strategies, understanding trends, expert insights/KOL views, and patient population in the 7MM.

A detailed review of current challenges in establishing the diagnosis.

Epidermolysis Bullosa Report Insights

Patient Population

Country-wise Epidemiology Distribution

Age-wise Cases of Epidermolysis Bullosa

Type-specific Cases of Epidermolysis Bullosa

Epidermolysis Bullosa Report Key Strengths

Eleven Years Forecast

The 7MM Coverage

Epidermolysis Bullosa Epidemiology Segmentation

Epidermolysis Bullosa Report Assessment

Current Diagnostic Practices

Unmet Needs

Epidemiology Insights

What are the disease risk, burdens, and unmet needs of Epidermolysis Bullosa? What will be the growth opportunities across the 7MM concerning the patient population with Epidermolysis Bullosa?

What is the historical and forecasted Epidermolysis Bullosa patient pool in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan?

Which type of Epidermolysis Bullosa is the largest contributor?

What is the diagnosis rate of Epidermolysis Bullosa?

Reasons to Buy

Insights on patient burden/disease, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.

To understand the age-specific Epidermolysis Bullosa prevalent cases in varying geographies over the coming years.

A detailed overview of type-specific and gender-specific cases of Epidermolysis Bullosa is an inclusion.

To understand the perspective of key opinion leaders around the current challenges with establishing the diagnosis and insights on the recurrent and treatment-eligible patient pool.

Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.